摘要总结第十三届世界胃肠道肿瘤大会上报道的抗血管生成药物治疗结直肠癌( CRC)的最新研究成果,结合有关文献综述贝伐单抗在CRC治疗中的最新进展.从内科角度,强调贝伐单抗早期应用及早获益,持续应用更大获益,二线治疗疗效再度肯定.从外科角度,强调贝伐单抗新辅助治疗转移性结直肠癌( mCRC)肝转移,能显著提高缓解率和切除率,并有良好的耐受性,同时可减少化疗诱导的肝损伤,安全有效.

abstractsTo summarize the latest study results about anti-angiogenic therapy for colorectal cancer (CRC) reported in the 13th world congress on gastrointestinal cancer, and review the latest progress of bevacizumab in treating colorectal carcinoma combined with related literatures.From the internal medicine point of view, bevacizumab is emphasized that to be applied earlier would gain benefit as soon as possible,and to be applied continuously would gain more benefit.The curative effect of second-line therapy has been confirmed renewedly.In the surgery point, bevacizumab neoadjuvant treating liver metastases in metastatic colorectal carcinoma (mCRC) can improve the disease-free rate and the operable rate significantly, and has favorable tolerance.In addition,bevacizumab can decrease the hepatic injury induced by chemotherapy safely and effectively.